Close Menu

NEW YORK — Exagen reported on Tuesday a 15 percent year-over-year drop in its second quarter revenues on lower testing revenue.

For the three-month period ended June 30, Exagen's revenues were $8.9 million versus $10.5 million a year earlier, topping the consensus Wall Street estimate of $4.7 million. Testing revenue dropped 33 percent to $6.8 million year over year from $10.2 million, which the San Diego-based autoimmune diagnostics company attributed to lower testing volumes amid the SARS-CoV-2 pandemic and a decrease in average reimbursement per test.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.